대한전기학회논문지:시스템및제어부문D (The Transactions of the Korean Institute of Electrical Engineers D)

대한전기학회 (The Korean Institute of Electrical Engineers)
권호 표지

일정한 약물 투여를 통한 HIV 감염자의 long-term Non-Progressor 전환 치료

Treatment for HIV-Infected Patients to Induce Long-Term Non-Progressor with Constant Drug Dosage

  • 김진영 (한양대 공대 전자전기컴퓨터공학부) ;
  • 김원희 ((주)삼성전자 TN총괄) ;
  • 고지현 (McGill University 의대 신경과학부) ;
  • 정한별 (한양대 공대 전기공학과) ;
  • 정정주 (한양대 공대 전자전기컴퓨터공학부)
  • 발행 : 2005.04.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This paper presents a therapy that uses a constant drug dosage for leading HIV-infected patient to LTNP (Long-Term Non-Progressor). Based on analysis of CTLp (Cytotoxic T Lymphocyte precursor) concentration at equilibrium point and its bifurcation, we found the therapy with a drug whose efficacy is less than a certain level brings higher CTLp concentration at the equilibrium point. We observed a treatment with constant drug dosage whose efficacy is less than full treatment may lead HIV-infected patient to LTNP. It turns out that the treatment whose efficacy is less than full treatment is better in the point of performance on controllability.

키워드

참고문헌

  1. 'What is AIDS,' factsheets, AIDS.org, November 22, 2003. [Online] Available: http://www.aids.org/factSheets/101-What-is-AIDS.html
  2. D. Douek, J. Brenchley, M. Betts, D. Ambrozak, B. Hill, Y. Okamoto, J. Casazza, J. Kuruppu, K. Kunstman, S. Wollnsky, Z. Grossman, M. Dybul, A. Oxenlus, D. Price, M. Conners, and R. Koup, 'HIV preferentially infects HIV-specific CD4+ T cells,' Nature, vol. 417, pp. 95-98, 2002 https://doi.org/10.1038/417095a
  3. C. A. Janeway, P. Travers, M. Walport, and M. Shlomchik, 'Immunobiology,' Garland Churchill Livingstone, 2001
  4. S. Bonhoeffer, M. Rembiszewski, G. M. Ortiz, D. F. Nixon, 'Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection,' AIDS, vol. 14, pp. 2313-2322, 2000 https://doi.org/10.1097/00002030-200010200-00012
  5. D. Wodarz and M. A. Nowak, 'Specific therapy regimes could lead to long-term immunological control of HIV,' PNAS, vol. 96, pp. 14464-14469, December 1999 https://doi.org/10.1073/pnas.96.25.14464
  6. D. Wodarz, 'Helper-dependent vs. helper -independent CTL responses in HIV infection: implications for drug therapy and resistance,' J. Theor. Biol., vol. 213, pp. 447-459, August 2001 https://doi.org/10.1006/jtbi.2001.2426
  7. H. Shim, S. J. Han, C. C. Chung, S. W. Nam and J. H. Seo, 'Optimal scheduling of drug treatment for HIV infection: continuous dose control and receding horizon control,' International Journal of Control, Automation, and Systems, vol. 1. no. 3, pp. 282-288, 2003
  8. 허영희, 고지현, 김진영, 정정주, 남상원, 심형보, 'HIV 동역학과 최적 제어를 이용한 약물 치료에 관한 고찰,' Journal of Control, Automation and Systems Engineering, vol. 10, No.6, pp. 475-486, June 2004 https://doi.org/10.5302/J.ICROS.2004.10.6.475
  9. 'Treatment interruptions,' factsheets, AIDS.org, April, 2003. [Online] Available: http://www.aids.org/factSheets/406-Treatment- Interruptions.html
  10. R. Zurakowski and A. R. Teel, 'Enhancing immune response to HIV infection using MPC-based treatment scheduling,' In proceedings of American Control Conference, pp. 1182-1187, 2003 https://doi.org/10.1109/ACC.2003.1239748
  11. J. H. Ko, W. H. Kim, and C. C. Chung, 'Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability,' In Proc. of IEEE Conference on Decision and Control, pp. 1055-1060, 2004
  12. 'Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,' aidsinfo. nih.gov, March 23, 2004. [Online] Available: http://www.aidsinfo.nih.gov/guidlines/adult/AA_032304.html
  13. H. Chang, H. Shim, and J. Seo, 'Control of immune response of HIV infection model by gradual reduction of drug dose,' In Proc. of Conference on Decision and Control, pp. 1048-1054, 2004
  14. A. M. Jeffrey, X. Xia, and I. K. Craig, 'When to inititate HIV therapy: a control theoretic approach,' IEEE Trans. On Biomedical Engineering, vol. 50, no 11, pp. 1213-1220, Nov. 2003 https://doi.org/10.1109/TBME.2003.818465
  15. S. Kubiak, H. Lehr, R. Levy, T. Moeller, A. Parker and E. Swim, 'Control of HIV infection through structured treatment interruptions with recommendations for experimental protocol,' CRSC Technical Report (CRSC-TR01-27) pp. 1-20, 2001. (Also at http://www.math.montana.edu/-parker.)
  16. R. A. Arnaout, M. A. Martin, and D. Wodarz, 'HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?,' In Proceedings of the Royal Society of London. series Biological sciences, vol. 267, pp. 1347-1354, 2000
  17. H. Shim, H. Chang, and J. Seo, 'Non-vanishing basin of attraction with respect to a parametric variation and center manifold,' In proceedings of IEEE Conference on Decision and Control, pp. 2984-2989, 2004
  18. J. Gerstoft, O. Kirk, N. Obel, C. Pedersen, L. Mathiesen, H. Nielsen, TL. Katzenstein, JD. Lundgren, 'Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir,' AIDS, vol. 17, pp. 2045-2052, 2003 https://doi.org/10.1097/00002030-200309260-00005
  19. M. A. Nowak and R. M. May,'Virus Dynamics: Mathematical principles of immunology and virology,' Oxford University Press, 2000
  20. M. Clerici, E. Seminari, F. Suter, et al, 'Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy treated and antiretroviral-napatient with undetectable viraemia,' AIDS, vol. 14, pp. 109-116, 2000 https://doi.org/10.1097/00002030-200001280-00005